Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Expression, Pharmacological Profile, and Functional Coupling of A2B Receptors in a Recombinant System and in Peripheral Blood Cells Using a Novel Selective Antagonist Radioligand, [3H]MRE 2029-F20

Stefania Gessi, Katia Varani, Stefania Merighi, Elena Cattabriga, Cecilia Pancaldi, Youri Szabadkai, Rosario Rizzuto, Karl-Norbert Klotz, Edward Leung, Stephen Mac Lennan, Pier Giovanni Baraldi and Pier Andrea Borea
Molecular Pharmacology June 2005, 67 (6) 2137-2147; DOI: https://doi.org/10.1124/mol.104.009225
Stefania Gessi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katia Varani
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stefania Merighi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elena Cattabriga
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cecilia Pancaldi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Youri Szabadkai
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rosario Rizzuto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karl-Norbert Klotz
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Edward Leung
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen Mac Lennan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pier Giovanni Baraldi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pier Andrea Borea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

In this study, we compared the pharmacological and biochemical characteristics of A2B adenosine receptors in recombinant (hA2BHEK293 cells) and native cells (neutrophils, lymphocytes) by using a new potent 8-pyrazole xanthine derivative, [3H]N-benzo[1,3]dioxol-5-yl-2-[5-(1,3-dipropyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)-1-methyl-1H-pyrazol-3-yl-oxy]-acetamide] ([3H]MRE 2029-F20), that has high affinity and selectivity for hA2B versus hA1,hA2A, and hA3 subtypes. [3H]MRE 2029-F20 bound specifically to the hA2B receptor stably transfected in human embryonic kidney (HEK) 293 cells with KD of 2.8 ± 0.2 nM and Bmax of 450 ± 42 fmol/mg of protein. Saturation experiments of [3H]MRE 2029-F20 binding in human neutrophils and lymphocytes detected a single high-affinity binding site with KD values of 2.4 ± 0.5 and 2.7 ± 0.7 nM, respectively, and Bmax values of 79 ± 10 and 54 ± 8 fmol/mg of protein, respectively, in agreement with real-time reverse transcription polymerase chain reaction studies showing the presence of A2B mRNA. The rank order of potency of typical adenosine ligands with recombinant hA2B receptors was consistent with that typically found for interactions with the A2B subtype and was also similar in peripheral blood cells. 5′-N-Ethyl-carboxamidoadenosine stimulated cAMP accumulation in both hA2BHEK293 and native cells, whereas phospholipase C activation was observed in recombinant receptors and endogenous subtypes expressed in neutrophils but not in lymphocytes. MRE 2029-F20 was revealed to be a potent antagonist in counteracting the agonist effect in both signal transduction pathways. In conclusion, [3H]MRE 2029-F20 is a selective and high-affinity radioligand for the hA2B adenosine subtype and may be used to quantify A2B endogenous receptors. In this work, we demonstrated their presence and functional coupling in neutrophils and lymphocytes that play a role in inflammatory processes in which A2B receptors may be involved.

  • Received December 6, 2004.
  • Accepted March 22, 2005.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology: 67 (6)
Molecular Pharmacology
Vol. 67, Issue 6
1 Jun 2005
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Expression, Pharmacological Profile, and Functional Coupling of A2B Receptors in a Recombinant System and in Peripheral Blood Cells Using a Novel Selective Antagonist Radioligand, [3H]MRE 2029-F20
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Expression, Pharmacological Profile, and Functional Coupling of A2B Receptors in a Recombinant System and in Peripheral Blood Cells Using a Novel Selective Antagonist Radioligand, [3H]MRE 2029-F20

Stefania Gessi, Katia Varani, Stefania Merighi, Elena Cattabriga, Cecilia Pancaldi, Youri Szabadkai, Rosario Rizzuto, Karl-Norbert Klotz, Edward Leung, Stephen Mac Lennan, Pier Giovanni Baraldi and Pier Andrea Borea
Molecular Pharmacology June 1, 2005, 67 (6) 2137-2147; DOI: https://doi.org/10.1124/mol.104.009225

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Expression, Pharmacological Profile, and Functional Coupling of A2B Receptors in a Recombinant System and in Peripheral Blood Cells Using a Novel Selective Antagonist Radioligand, [3H]MRE 2029-F20

Stefania Gessi, Katia Varani, Stefania Merighi, Elena Cattabriga, Cecilia Pancaldi, Youri Szabadkai, Rosario Rizzuto, Karl-Norbert Klotz, Edward Leung, Stephen Mac Lennan, Pier Giovanni Baraldi and Pier Andrea Borea
Molecular Pharmacology June 1, 2005, 67 (6) 2137-2147; DOI: https://doi.org/10.1124/mol.104.009225
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Analgesic Effects and Mechanisms of Licochalcones
  • Induced Fit Ligand Binding to CYP3A4
  • Englerin A Inhibits T-Type Channels
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics